{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T03:03:06Z","timestamp":1793674986698,"version":"4.5.1"},"reference-count":49,"publisher":"American Society of Hematology","issue":"12","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,6,25]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Graft-versus-host disease (GVHD) is a major cause of nonrelapse mortality (NRM) after allogeneic hematopoietic cell transplantation. Algorithms containing either the gastrointestinal (GI) GVHD biomarker amphiregulin (AREG) or a combination of 2 GI GVHD biomarkers (suppressor of tumorigenicity-2 [ST2]\u00a0+ regenerating family member 3 alpha [REG3\u03b1]) when measured at GVHD diagnosis are validated predictors of NRM risk but have never been assessed in the same patients using identical statistical methods. We measured the serum concentrations of ST2, REG3\u03b1, and AREG by enzyme-linked immunosorbent assay at the time of GVHD diagnosis in 715 patients divided by the date of transplantation into training (2004-2015) and validation (2015-2017) cohorts. The training cohort (n\u00a0= 341) was used to develop algorithms for predicting the probability of 12-month NRM that contained all possible combinations of 1 to 3 biomarkers and a threshold corresponding to the concordance probability was used to stratify patients for the risk of NRM. Algorithms were compared with each other based on several metrics, including the area under the receiver operating characteristics curve, proportion of patients correctly classified, sensitivity, and specificity using only the validation cohort (n\u00a0= 374). All algorithms were strong discriminators of 12-month NRM, whether or not patients were systemically treated (n\u00a0=\u00a0321). An algorithm containing only ST2\u00a0+ REG3\u03b1 had the highest area under the receiver operating characteristics curve (0.757), correctly classified the most patients (75%), and more accurately risk-stratified those who developed Minnesota standard-risk GVHD and for patients who received posttransplant cyclophosphamide-based prophylaxis. An algorithm containing only AREG more accurately risk-stratified patients with Minnesota high-risk GVHD. Combining ST2, REG3\u03b1, and AREG into a single algorithm did not improve performance.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2023011049","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T11:21:09Z","timestamp":1718364069000},"page":"3284-3292","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":20,"title":["Amphiregulin, ST2, and REG3\u03b1 biomarker risk algorithms as predictors of nonrelapse mortality in patients with acute GVHD"],"prefix":"10.1182","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-7360-3986","authenticated-orcid":false,"given":"Aaron","family":"Etra","sequence":"first","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9268-9655","authenticated-orcid":false,"given":"Najla","family":"El Jurdi","sequence":"additional","affiliation":[{"name":"2Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7955-1119","authenticated-orcid":false,"given":"Nikolaos","family":"Katsivelos","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deukwoo","family":"Kwon","sequence":"additional","affiliation":[{"name":"3Department of Population Health Science and Policy, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Gergoudis","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Morales","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5274-1749","authenticated-orcid":false,"given":"Nikolaos","family":"Spyrou","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven","family":"Kowalyk","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0196-806X","authenticated-orcid":false,"given":"Paibel","family":"Aguayo-Hiraldo","sequence":"additional","affiliation":[{"name":"4Division of Hematology, Oncology, and Blood and Marrow Transplantation, Children's Hospital Los Angeles, Los Angeles, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Akahoshi","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francis","family":"Ayuk","sequence":"additional","affiliation":[{"name":"5Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janna","family":"Baez","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian C.","family":"Betts","sequence":"additional","affiliation":[{"name":"2Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chantiya","family":"Chanswangphuwana","sequence":"additional","affiliation":[{"name":"6Blood and Marrow Transplantation Program, Chulalongkorn University, Bangkok, Thailand"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9554-1058","authenticated-orcid":false,"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"7Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Choe","sequence":"additional","affiliation":[{"name":"8Division of Hematology, James Cancer Center, The Ohio State University, Columbus, OH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7994-8974","authenticated-orcid":false,"given":"Zachariah","family":"DeFilipp","sequence":"additional","affiliation":[{"name":"7Hematopoietic Cell Transplant and Cellular Therapy Program, Massachusetts General Hospital, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sigrun","family":"Gleich","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1125-4060","authenticated-orcid":false,"given":"Elizabeth","family":"Hexner","sequence":"additional","affiliation":[{"name":"10Blood and Marrow Transplantation Program, Abramson Cancer Center, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5841-4105","authenticated-orcid":false,"given":"William J.","family":"Hogan","sequence":"additional","affiliation":[{"name":"11Division of Hematology, Mayo Clinic, Rochester, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[{"name":"9Department of Hematology and Oncology, Internal Medicine III, University of Regensburg, Regensburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carrie L.","family":"Kitko","sequence":"additional","affiliation":[{"name":"12Pediatric Stem Cell Transplant Program, Vanderbilt University Medical Center, Nashville, TN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabrina","family":"Kraus","sequence":"additional","affiliation":[{"name":"13Department of Internal Medicine II, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8226-471X","authenticated-orcid":false,"given":"Monzr","family":"Al Malki","sequence":"additional","affiliation":[{"name":"14Hematology\/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Margaret","family":"MacMillan","sequence":"additional","affiliation":[{"name":"2Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Attaphol","family":"Pawarode","sequence":"additional","affiliation":[{"name":"15Blood and Marrow Transplantation Program, University of Michigan, Ann Arbor, MI"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7346-2738","authenticated-orcid":false,"given":"Francesco","family":"Quagliarella","sequence":"additional","affiliation":[{"name":"16Ospedale Bambino Gesu', Rome, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7689-343X","authenticated-orcid":false,"given":"Muna","family":"Qayed","sequence":"additional","affiliation":[{"name":"17Aflac Cancer and Blood Disorders Center, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Reshef","sequence":"additional","affiliation":[{"name":"18Blood and Marrow Transplantation Program, Columbia University Medical Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Schechter","sequence":"additional","affiliation":[{"name":"19Division of Hematology\/Oncology\/BMT, The Hospital for Sick Children, University of Toronto, Toronto, ON, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid","family":"Vasova","sequence":"additional","affiliation":[{"name":"20Med. Klinik III\/Poliklinik, Universitatsklinik Erlangen, Erlangen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8078-8579","authenticated-orcid":false,"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"2Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9608-3482","authenticated-orcid":false,"given":"Matthias","family":"W\u00f6lfl","sequence":"additional","affiliation":[{"name":"21Pediatric Blood and Marrow Transplantation Program, Children\u2019s Hospital, University of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel","family":"Young","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9082-0680","authenticated-orcid":false,"given":"Ryotaro","family":"Nakamura","sequence":"additional","affiliation":[{"name":"14Hematology\/Hematopoietic Cell Transplant, City of Hope National Medical Center, Duarte, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James L. M.","family":"Ferrara","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5611-7828","authenticated-orcid":false,"given":"John E.","family":"Levine","sequence":"additional","affiliation":[{"name":"1The Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5054-9419","authenticated-orcid":false,"given":"Shernan","family":"Holtan","sequence":"additional","affiliation":[{"name":"2Hematology, Oncology and Transplant, University of Minnesota, Minneapolis, MN"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"issue":"4","key":"2024062514452777100_bib1","doi-asserted-by":"crossref","first-page":"229","DOI":"10.7326\/M19-2936","article-title":"Survival, nonrelapse mortality, and relapse-related mortality after allogeneic hematopoietic cell transplantation: comparing 2003-2007 versus 2013-2017 cohorts","volume":"172","author":"McDonald","year":"2020","journal-title":"Ann Intern Med"},{"key":"2024062514452777100_bib2","doi-asserted-by":"crossref","first-page":"605726","DOI":"10.3389\/fimmu.2021.605726","article-title":"GVHD prophylaxis 2020","volume":"12","author":"Gooptu","year":"2021","journal-title":"Front Immunol"},{"issue":"3","key":"2024062514452777100_bib3","doi-asserted-by":"crossref","first-page":"e132","DOI":"10.1016\/S2352-3026(18)30221-7","article-title":"Three prophylaxis regimens (tacrolimus, mycophenolate mofetil, and cyclophosphamide; tacrolimus, methotrexate, and bortezomib; or tacrolimus, methotrexate, and maraviroc) versus tacrolimus and methotrexate for prevention of graft-versus-host disease with haemopoietic cell transplantation with reduced-intensity conditioning: a randomised phase 2 trial with a non-randomised contemporaneous control group (BMT CTN 1203)","volume":"6","author":"Bolanos-Meade","year":"2019","journal-title":"Lancet Haematol"},{"issue":"10","key":"2024062514452777100_bib4","doi-asserted-by":"crossref","first-page":"681","DOI":"10.1016\/j.jtct.2022.07.013","article-title":"Characteristics of graft-versus-host disease (GvHD) after post-transplantation cyclophosphamide versus conventional GvHD prophylaxis","volume":"28","author":"Saliba","year":"2022","journal-title":"Transplant Cell Ther"},{"issue":"25","key":"2024062514452777100_bib5","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1056\/NEJMoa2215943","article-title":"Post-transplantation cyclophosphamide-based graft-versus-host disease prophylaxis","volume":"388","author":"Bola\u00f1os-Meade","year":"2023","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"2024062514452777100_bib6","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.bbmt.2015.01.001","article-title":"A\u00a0refined risk score for acute graft-versus-host disease that predicts response to initial therapy, survival, and transplant-related mortality","volume":"21","author":"MacMillan","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"2024062514452777100_bib7","doi-asserted-by":"crossref","first-page":"1495","DOI":"10.1182\/blood-2004-11-4557","article-title":"Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: a joint Societe Francaise de Greffe de Moelle et Therapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study","volume":"106","author":"Cahn","year":"2005","journal-title":"Blood"},{"issue":"2","key":"2024062514452777100_bib8","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3324\/haematol.2019.220970","article-title":"Validation of Minnesota acute graft-versus-host disease risk score","volume":"105","author":"MacMillan","year":"2020","journal-title":"Haematologica"},{"issue":"6","key":"2024062514452777100_bib9","doi-asserted-by":"crossref","first-page":"842","DOI":"10.3324\/haematol.2014.118471","article-title":"Effectiveness and safety of lower dose prednisone for initial treatment of acute graft-versus-host disease: a randomized controlled trial","volume":"100","author":"Mielcarek","year":"2015","journal-title":"Haematologica"},{"issue":"7","key":"2024062514452777100_bib10","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/j.bbmt.2020.04.023","article-title":"Sole upfront therapy with beclomethasone and budesonide for upper gastrointestinal acute graft-versus-host disease","volume":"26","author":"Frairia","year":"2020","journal-title":"Biol Blood Marrow Transplant"},{"issue":"9","key":"2024062514452777100_bib11","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1016\/j.bbmt.2014.05.023","article-title":"Etanercept plus topical corticosteroids as initial therapy for grade one acute graft-versus-host disease after allogeneic hematopoietic cell transplantation","volume":"20","author":"Gatza","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"issue":"5","key":"2024062514452777100_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1038\/s41409-020-01049-0","article-title":"Phase II trial of natalizumab with corticosteroids as initial treatment of gastrointestinal acute graft-versus-host disease","volume":"56","author":"Kekre","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"2024062514452777100_bib13","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1182\/asheducation-2018.1.221","article-title":"GVHD: biology matters","volume":"2018","author":"Ferrara","year":"2018","journal-title":"Hematology Am Soc Hematol Educ Program"},{"issue":"6","key":"2024062514452777100_bib14","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1056\/NEJMoa1213299","article-title":"ST2 as a marker for risk of therapy-resistant graft-versus-host disease and death","volume":"369","author":"Vander Lugt","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"308","key":"2024062514452777100_bib15","doi-asserted-by":"crossref","first-page":"308ra160","DOI":"10.1126\/scitranslmed.aab0166","article-title":"ST2 blockade reduces sST2-producing T cells while maintaining protective mST2-expressing T cells during graft-versus-host disease","volume":"7","author":"Zhang","year":"2015","journal-title":"Sci Transl Med"},{"issue":"25","key":"2024062514452777100_bib16","doi-asserted-by":"crossref","first-page":"6702","DOI":"10.1182\/blood-2011-08-375006","article-title":"Regenerating islet-derived 3-alpha is a biomarker of gastrointestinal graft-versus-host disease","volume":"118","author":"Ferrara","year":"2011","journal-title":"Blood"},{"issue":"11","key":"2024062514452777100_bib17","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.1172\/JCI99261","article-title":"Survival signal REG3alpha prevents crypt apoptosis to control acute gastrointestinal graft-versus-host disease","volume":"128","author":"Zhao","year":"2018","journal-title":"J\u00a0Clin Invest"},{"issue":"4","key":"2024062514452777100_bib18","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1038\/s41379-018-0170-z","article-title":"Amphiregulin in intestinal acute graft-versus-host disease: a possible diagnostic and prognostic aid","volume":"32","author":"Amin","year":"2019","journal-title":"Mod Pathol"},{"key":"2024062514452777100_bib19","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fimmu.2017.00475","article-title":"The ST2\/IL-33 axis in immune cells during inflammatory diseases","volume":"8","author":"Griesenauer","year":"2017","journal-title":"Front Immunol"},{"issue":"22","key":"2024062514452777100_bib20","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1056\/NEJMra1609337","article-title":"Acute graft-versus-host disease - biologic process, prevention, and therapy","volume":"377","author":"Zeiser","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"2024062514452777100_bib21","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.immuni.2015.01.020","article-title":"Emerging functions of amphiregulin in orchestrating immunity, inflammation, and tissue repair","volume":"42","author":"Zaiss","year":"2015","journal-title":"Immunity"},{"issue":"4","key":"2024062514452777100_bib22","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1038\/s41385-022-00527-6","article-title":"Challenges and opportunities targeting mechanisms of epithelial injury and recovery in acute intestinal graft-versus-host disease","volume":"15","author":"Jansen","year":"2022","journal-title":"Mucosal Immunol"},{"issue":"34","key":"2024062514452777100_bib23","doi-asserted-by":"crossref","first-page":"10762","DOI":"10.1073\/pnas.1509070112","article-title":"IL-33 promotes an innate immune pathway of intestinal tissue protection dependent on amphiregulin-EGFR interactions","volume":"112","author":"Monticelli","year":"2015","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"2","key":"2024062514452777100_bib24","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/nri3349","article-title":"Innate lymphoid cells--how did we miss them?","volume":"13","author":"Walker","year":"2013","journal-title":"Nat Rev Immunol"},{"issue":"7","key":"2024062514452777100_bib25","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1182\/bloodadvances.2019001259","article-title":"Facilitating resolution of life-threatening acute GVHD with human chorionic gonadotropin and epidermal growth factor","volume":"4","author":"Holtan","year":"2020","journal-title":"Blood Adv"},{"issue":"Suppl 1","key":"2024062514452777100_bib26","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1182\/blood-2022-168793","article-title":"Donor-derived amphiregulin drives CD4+ T cell expansion and promotes tissue pathology after experimental allogeneic BMT","volume":"140","author":"Ito","year":"2022","journal-title":"Blood"},{"issue":"20","key":"2024062514452777100_bib27","doi-asserted-by":"crossref","first-page":"3183","DOI":"10.1182\/blood-2014-10-606830","article-title":"The IL-33\/ST2 axis augments effector T-cell responses during acute GVHD","volume":"125","author":"Reichenbach","year":"2015","journal-title":"Blood"},{"issue":"12","key":"2024062514452777100_bib28","doi-asserted-by":"crossref","first-page":"3707","DOI":"10.1182\/bloodadvances.2022007296","article-title":"Assessment of systemic and gastrointestinal tissue damage biomarkers for GVHD risk stratification","volume":"6","author":"Etra","year":"2022","journal-title":"Blood Adv"},{"issue":"3","key":"2024062514452777100_bib29","doi-asserted-by":"crossref","first-page":"e89798","DOI":"10.1172\/jci.insight.89798","article-title":"An early-biomarker algorithm predicts lethal graft-versus-host disease and survival","volume":"2","author":"Hartwell","year":"2017","journal-title":"JCI Insight"},{"issue":"16","key":"2024062514452777100_bib30","doi-asserted-by":"crossref","first-page":"4763","DOI":"10.1182\/bloodadvances.2022007477","article-title":"Prospective external validation of biomarkers to predict acute graft-versus-host disease severity","volume":"6","author":"Robin","year":"2022","journal-title":"Blood Adv"},{"issue":"17","key":"2024062514452777100_bib31","doi-asserted-by":"crossref","first-page":"5152","DOI":"10.1182\/bloodadvances.2023009929","article-title":"The utility of biomarkers in acute GVHD prognostication","volume":"7","author":"Spyrou","year":"2023","journal-title":"Blood Adv"},{"issue":"15","key":"2024062514452777100_bib32","doi-asserted-by":"crossref","first-page":"1882","DOI":"10.1182\/bloodadvances.2018017343","article-title":"Amphiregulin modifies the Minnesota acute graft-versus-host disease risk score: results from BMT CTN 0302\/0802","volume":"2","author":"Holtan","year":"2018","journal-title":"Blood Adv"},{"issue":"19","key":"2024062514452777100_bib33","doi-asserted-by":"crossref","first-page":"2350","DOI":"10.1182\/blood-2015-09-669846","article-title":"Late acute graft-versus-host disease: a prospective analysis of clinical outcomes and circulating angiogenic factors","volume":"128","author":"Holtan","year":"2016","journal-title":"Blood"},{"issue":"5","key":"2024062514452777100_bib34","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood.2022017442","article-title":"Effective treatment of low-risk acute GVHD with itacitinib monotherapy","volume":"141","author":"Etra","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2024062514452777100_bib35","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1182\/blood.2019003125","article-title":"Randomized multicenter trial of sirolimus vs prednisone as initial therapy for standard-risk acute GVHD: the BMT CTN 1501 trial","volume":"135","author":"Pidala","year":"2020","journal-title":"Blood"},{"issue":"17","key":"2024062514452777100_bib36","doi-asserted-by":"crossref","first-page":"5189","DOI":"10.1182\/bloodadvances.2023009853","article-title":"Phase 2 study of natalizumab plus standard corticosteroid treatment for high-risk acute graft-versus-host disease","volume":"7","author":"Al Malki","year":"2023","journal-title":"Blood Adv"},{"issue":"20","key":"2024062514452777100_bib37","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/jnci\/djn326","article-title":"Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design","volume":"100","author":"Pepe","year":"2008","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"1","key":"2024062514452777100_bib38","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai Acute GVHD International Consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"23","key":"2024062514452777100_bib39","doi-asserted-by":"crossref","first-page":"2676","DOI":"10.1002\/sim.4509","article-title":"Classification accuracy and cut point selection","volume":"31","author":"Liu","year":"2012","journal-title":"Stat Med"},{"issue":"4","key":"2024062514452777100_bib40","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1002\/gepi.20211","article-title":"A\u00a0balanced accuracy function for epistasis modeling in imbalanced datasets using multifactor dimensionality reduction","volume":"31","author":"Velez","year":"2007","journal-title":"Genet Epidemiol"},{"issue":"3","key":"2024062514452777100_bib41","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"issue":"1","key":"2024062514452777100_bib42","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","article-title":"Controlling the false discovery rate: a practical and powerful approach to multiple testing","volume":"57","author":"Benjamini","year":"1995","journal-title":"J\u00a0R Stat Soc Series B"},{"issue":"446","key":"2024062514452777100_bib43","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1080\/01621459.1999.10474144","article-title":"A\u00a0proportional hazards model for the subdistribution of a competing risk","volume":"94","author":"Fine","year":"1999","journal-title":"J\u00a0Am Stat Assoc"},{"issue":"3","key":"2024062514452777100_bib44","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1214\/aos\/1176350951","article-title":"A\u00a0class of K-Sample tests for comparing the cumulative incidence of a competing risk","volume":"16","author":"Gray","year":"1988","journal-title":"Ann Statist"},{"issue":"24","key":"2024062514452777100_bib45","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1002\/sim.2864","article-title":"Analyzing survival curves at a fixed point in time","volume":"26","author":"Klein","year":"2007","journal-title":"Stat Med"},{"issue":"1-2","key":"2024062514452777100_bib46","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/S0166-4328(01)00297-2","article-title":"Controlling the false discovery rate in behavior genetics research","volume":"125","author":"Benjamini","year":"2001","journal-title":"Behav Brain Res"},{"issue":"17","key":"2024062514452777100_bib47","doi-asserted-by":"crossref","first-page":"1865","DOI":"10.1200\/JCO.20.01086","article-title":"Phase II trial of costimulation blockade with abatacept for prevention of acute GVHD","volume":"39","author":"Watkins","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"5","key":"2024062514452777100_bib48","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.3324\/haematol.2020.265769","article-title":"Improved outcome of patients with graft-versus-host disease after allogeneic hematopoietic cell transplantation for hematologic malignancies over time: an EBMT mega-file study","volume":"107","author":"Greinix","year":"2022","journal-title":"Haematologica"},{"issue":"11","key":"2024062514452777100_bib49","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1038\/nri.2016.95","article-title":"Interleukin-33 in health and disease","volume":"16","author":"Liew","year":"2016","journal-title":"Nat Rev Immunol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3284\/2231994\/blooda_adv-2023-011049-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/8\/12\/3284\/2231994\/blooda_adv-2023-011049-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T10:46:41Z","timestamp":1719312401000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/8\/12\/3284\/515782\/Amphiregulin-ST2-and-REG3-biomarker-risk"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,6,25]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2023011049","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]}}}